Holen Sie sich die Stockscreener-App
0.5302
0.71%
-0.0038
Handel nachbörslich:
.53
-0.0002
-0.04%
Schlusskurs vom Vortag:
$0.534
Offen:
$0.5192
24-Stunden-Volumen:
9.05M
Relative Volume:
1.61
Marktkapitalisierung:
$159.97M
Einnahmen:
$52.29M
Nettoeinkommen (Verlust:
$-134.84M
KGV:
-0.7069
EPS:
-0.75
Netto-Cashflow:
$-117.11M
1W Leistung:
-2.05%
1M Leistung:
-0.90%
6M Leistung:
-38.33%
1J Leistung:
-33.58%
1-Tages-Spanne:
$0.47
$0.5424
1-Wochen-Bereich:
$0.47
$0.5557
52-Wochen-Spanne:
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Firmenname
Sangamo Therapeutics Inc
Sektor
Branche
Telefon
(510) 970-6000
Adresse
501 CANAL BLVD., RICHMOND, CA
Vergleichen Sie SGMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.5302 | 162.74M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Hochstufung | Truist | Hold → Buy |
| 2024-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-01-07 | Fortgesetzt | Guggenheim | Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-12-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-09-08 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | SunTrust | Buy |
| 2019-08-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-10-10 | Eingeleitet | Guggenheim | Buy |
| 2018-06-20 | Eingeleitet | BofA/Merrill | Buy |
| 2017-11-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2016-11-01 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-10-19 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-10-23 | Fortgesetzt | Jefferies | Buy |
| 2013-05-03 | Eingeleitet | BioLogic Equity Research | Sell |
| 2011-02-23 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-07-29 | Bestätigt | Wedbush | Outperform |
| 2009-10-19 | Eingeleitet | Brean Murray | Sell |
| 2009-10-07 | Bestätigt | Leerink Swann | Outperform |
| 2009-08-25 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten
Is Sangamo Therapeutics Inc. benefiting from interest rate changesPortfolio Value Report & Real-Time Market Sentiment Reports - khodrobank.com
Sangamo Therapeutics: A High-Conviction Biotech Play with a Clear Path to FDA Approval in 2026 - AInvest
Sangamo reports promising data for Fabry disease gene therapy - Investing.com
Sangamo Biosciences Reveals Promising Fabry Disease Study Results - TipRanks
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 - The Manila Times
1.97 mL/min Kidney Function Improvement: Sangamo's One-Time Gene Therapy Could Transform Fabry Disease Care - Stock Titan
Will Sangamo Therapeutics Inc. stock recover after recent dropJuly 2025 Decliners & Verified Swing Trading Watchlists - Newser
Published on: 2025-09-04 02:16:59 - Newser
Will Sangamo Therapeutics Inc. outperform its industry peersJuly 2025 Volume & Momentum Based Trading Ideas - khodrobank.com
Chart based analysis of Sangamo Therapeutics Inc. trendsJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - Newser
Evaluating Sangamo Therapeutics Inc. with trendline analysisAnalyst Downgrade & Community Consensus Stock Picks - Newser
Measuring Sangamo Therapeutics Inc.’s beta against major indices2025 Price Action Summary & Step-by-Step Swing Trade Plans - Newser
What the charts say about Sangamo Therapeutics Inc. todayFed Meeting & Low Drawdown Trading Techniques - Newser
Will Sangamo Therapeutics Inc. benefit from current market trendsJuly 2025 Momentum & Technical Confirmation Alerts - khodrobank.com
Smart tools for monitoring Sangamo Therapeutics Inc.’s price actionEarnings Overview Summary & Smart Money Movement Alerts - Newser
What’s the profit margin of Sangamo Therapeutics Inc.July 2025 Summary & Risk Adjusted Buy and Sell Alerts - khodrobank.com
What MACD signals say about Sangamo Therapeutics Inc.Rate Hike & Fast Momentum Stock Entry Tips - Newser
What institutional flow reveals about Sangamo Therapeutics Inc.Bull Run & Weekly High Potential Stock Alerts - Newser
Analyzing Sangamo Therapeutics Inc. with risk reward ratio charts2025 EndofYear Setup & Verified Chart Pattern Signals - Newser
Real time breakdown of Sangamo Therapeutics Inc. stock performance2025 Short Interest & Advanced Swing Trade Entry Plans - Newser
Should I buy Sangamo Therapeutics Inc. stock now2025 Biggest Moves & Daily Growth Stock Investment Tips - khodrobank.com
Sangamo Therapeutics Inc.’s volatility index tracking explainedTrade Volume Report & Short-Term Trading Opportunity Alerts - Newser
Is Sangamo Therapeutics Inc.’s ROE strong enough2025 Growth vs Value & Weekly Breakout Watchlists - khodrobank.com
Should you hold or exit Sangamo Therapeutics Inc. nowLayoff News & Risk Controlled Stock Pick Alerts - Newser
Sangamo Therapeutics Inc. stock trend outlook and recovery pathEarnings Growth Summary & Real-Time Chart Breakout Alerts - Newser
Technical analysis overview for Sangamo Therapeutics Inc. stock2025 Stock Rankings & Consistent Profit Alerts - Newser
Will Sangamo Therapeutics Inc. bounce back from current support2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
Is Sangamo Therapeutics Inc. benefiting from innovation trendsJuly 2025 Patterns & Fast Exit and Entry Trade Guides - khodrobank.com
Is Sangamo Therapeutics Inc. a cyclical or defensive stockPortfolio Profit Report & Community Verified Watchlist Alerts - khodrobank.com
CEO Moves: Should I buy Sangamo Therapeutics Inc. stock now2025 Risk Factors & Weekly Stock Breakout Alerts - خودرو بانک
Does Sangamo Therapeutics Inc. fit your quant trading modelWeekly Trade Report & Weekly Hot Stock Watchlists - Newser
What is Sangamo Therapeutics Inc.’s valuation compared to sectorJuly 2025 Opening Moves & Real-Time Chart Pattern Alerts - khodrobank.com
Analyzing Sangamo Therapeutics Inc. with multi timeframe chartsInflation Watch & Real-Time Buy Signal Alerts - Newser
What are Sangamo Therapeutics Inc.’s recent SEC filings showingWeekly Stock Summary & Daily Growth Stock Tips - khodrobank.com
Developing predictive dashboards with Sangamo Therapeutics Inc. data2025 Risk Factors & Growth-Oriented Investment Plans - Newser
Will Sangamo Therapeutics Inc. outperform the marketTrade Volume Report & Real-Time Volume Trigger Notifications - Newser
Finanzdaten der Sangamo Therapeutics Inc-Aktie (SGMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):